https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-ovarian-cancer-bot-bal BiopharmaWatch en 2026-10-04T02:42:00.000Z Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026 https://www.biopharmawatch.com/news/AGEN/riassunto-agenus-segnala-una-sopravvivenza-tre-anni-stimata-al-48 BiopharmaWatch en 2026-10-04T02:42:00.000Z Riassunto: Agenus segnala una sopravvivenza a tre anni stimata al 48% con BOT+BAL nel tumore ovarico recidivante all'IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-rate-ovarian-cancer BiopharmaWatch en 2026-10-04T02:41:00.000Z Samenvatting: Agenus rapporteert een geschatte driejarige overleving van 48% met BOT+BAL bij recidiverende eierstokkanker tijdens IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-dreijahresueberlebensrate-eierstockkrebs BiopharmaWatch en 2026-10-04T02:40:00.000Z Agenus meldet auf der IGCS 2026 eine geschätzte Dreijahresüberlebensrate von 48 % mit BOT+BAL bei rezidivierendem Eierstockkrebs https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-phase-2-results-ovarian-cancer BiopharmaWatch en 2026-10-03T19:40:00.000Z Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-bot-bal-ovarian-cancer BiopharmaWatch en 2026-10-03T14:50:00.000Z Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 https://www.biopharmawatch.com/news/ACOG/alpha-cognition-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T23:06:00.000Z Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/XERS/xeris-announces-inducement-grants-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-10-02T21:00:00.000Z Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NVO/novo-update-denecimig-bla-us BiopharmaWatch en 2026-10-02T20:53:00.000Z Novo provides update on the denecimig Biologics License Application (BLA) in the US https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-special-stock-dividend BiopharmaWatch en 2026-10-02T20:35:00.000Z Jaguar Health Announces a Special Stock Dividend https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IMA/imagenebio-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MLYS/lorundrostat-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-02T20:30:00.000Z Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 https://www.biopharmawatch.com/news/VTAK/catheter-precision-changes-name-ticker-symbol-flyte-aviation BiopharmaWatch en 2026-10-02T20:30:00.000Z Catheter Precision to Change its Name and Ticker Symbol to Flyte Aviation and “VJET” and Effect 1-for-10 Reverse Stock Split, Monday, October 5, at Market Open https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NRSN/neurosense-update-nasdaq-listing-compliance BiopharmaWatch en 2026-10-02T20:15:00.000Z NeuroSense Provides Update on Nasdaq Listing Compliance https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-02T20:05:00.000Z Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-02T20:05:00.000Z Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PETS/petmeds-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-02T20:05:00.000Z PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-inducement-awards-20261002 BiopharmaWatch en 2026-10-02T20:05:00.000Z Spyre Therapeutics Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:05:00.000Z Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/APMD/apnimed-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-02T20:05:00.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GLUE/monte-rosa-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CARL/carlsmed-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-02T20:01:00.000Z Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-nasdaq-rule BiopharmaWatch en 2026-10-02T20:01:00.000Z Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-inducement-grants-nasdaq-rule BiopharmaWatch en 2026-10-02T20:01:00.000Z Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-october-2026 BiopharmaWatch en 2026-10-02T20:01:00.000Z Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:00:00.000Z Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-fda-approval-untreated-cll-sll BiopharmaWatch en 2026-10-02T19:05:00.000Z Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL https://www.biopharmawatch.com/news/BLCO/dryeye-rescue-exclusive-distributor-scoutpro-bausch-lomb BiopharmaWatch en 2026-10-02T18:47:00.000Z DryEye Rescue Becomes Exclusive U.S. Distributor of ScoutPro by Bausch + Lomb https://www.biopharmawatch.com/news/QFIN/qfin-holdings-class-action-lawsuit BiopharmaWatch en 2026-10-02T18:31:00.000Z Shareholders who lost money in Qfin Holdings, Inc. (NASDAQ: QFIN) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/GMAB/genmab-major-shareholder-announcement BiopharmaWatch en 2026-10-02T17:50:23.000Z Major Shareholder Announcement https://www.biopharmawatch.com/news/SNY/sanofi-karl-anthony-towns-covid-19-vaccination-awareness BiopharmaWatch en 2026-10-02T15:57:00.000Z Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID® https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-sitc-2026-presentation BiopharmaWatch en 2026-10-02T15:46:00.000Z Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 https://www.biopharmawatch.com/news/BIIB/biogen-litifilimab-phase-2-results-cutaneous-lupus BiopharmaWatch en 2026-10-02T15:20:00.000Z Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus https://www.biopharmawatch.com/news/PFE/pfizer-litfulo-improves-repigmentation-vitiligo BiopharmaWatch en 2026-10-02T15:15:00.000Z Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo https://www.biopharmawatch.com/news/BMRN/biomarin-five-year-phase-3-data-pombiliti-opfolda BiopharmaWatch en 2026-10-02T15:06:10.769Z BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-zugocabtagene-geleucel-acr-2026 BiopharmaWatch en 2026-10-02T14:15:00.000Z CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 https://www.biopharmawatch.com/news/TVTX/travere-present-new-data-filspari-as-foundational-treatment BiopharmaWatch en 2026-10-02T14:00:00.000Z Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/ICU/seastar-medical-late-breaking-presentation-asn-kidney-week-2026 BiopharmaWatch en 2026-10-02T13:43:00.000Z SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026